(Q26770548)

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Overcoming insulin resistance with ciliary neurotrophic factor

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

CNTF: a target therapeutic for obesity-related metabolic disease?

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Lifetime risk and projected population prevalence of diabetes

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Human IL6 enhances leptin action in mice

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Neuropoietic cytokines in the hematopoietic fold

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 and its receptors: a highly regulated and dynamic system

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Plasticity and cross-talk of interleukin 6-type cytokines

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Cardiotrophin-1: A multifaceted cytokine.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Recombinant human ciliary neurotrophic factor reduces weight partly by regulating nuclear respiratory factor 1 and mitochondrial transcription factor A.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

The ciliary neurotrophic factor and its receptor, CNTFR alpha

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Leptin and ciliary neurotropic factor (CNTF) inhibit fasting-induced suppression of luteinizing hormone release in rats: role of neuropeptide Y.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Inflammation and metabolic disorders

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Effects of acute exercise and training on insulin action and sensitivity: focus on molecular mechanisms in muscle

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Genotype, obesity and cardiovascular disease--has technical and social advancement outstripped evolution?

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

gp130 signaling in proopiomelanocortin neurons mediates the acute anorectic response to centrally applied ciliary neurotrophic factor

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Ciliary neurotrophic factor protects mice against streptozotocin-induced type 1 diabetes through SOCS3: the role of STAT1/STAT3 ratio in β-cell death

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates interleukin-6 receptor-dependent but retains CNTF receptor-dependent signaling via glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR).

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

The regulation and activation of ciliary neurotrophic factor signaling proteins in adipocytes

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Targeting gp130 to prevent inflammation and promote insulin action.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

How obesity causes diabetes: not a tall tale

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Muscle as an endocrine organ: focus on muscle-derived interleukin-6.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Obesity is associated with macrophage accumulation in adipose tissue

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

gp130 receptor ligands as potential therapeutic targets for obesity

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Transgenic blockade of interleukin 6 transsignaling abrogates inflammation

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Metabolic remodeling in adipocytes promotes ciliary neurotrophic factor-mediated fat loss in obesity

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 stimulates lipolysis and fat oxidation in humans

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Elevated Levels of Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after Weight Loss

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Ciliary neurotrophic factor maintains motoneurons and their target muscles in developing rats.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Direct effects of ciliary neurotrophic factor on brown adipocytes: evidence for a role in peripheral regulation of energy homeostasis

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Projecting the number of patients with end-stage renal disease in the United States to the year 2015

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

The gp130 receptor cytokine family: regulators of adipocyte development and function.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Oncostatin m modulation of lipid storage

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Obesity: pathophysiology and intervention

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

1 reference

https://api.crossref.org/works/10.1242%2FJEB.129213

7 January 2021